These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31735793)

  • 1. Pregnant Patient on Hemodialysis Who Showed Remarkable Improvement of Severe Hyperparathyroidism by Strict Serum Phosphorus Control.
    Ito J; Fujii H; Kono K; Goto S; Nishi S
    Intern Med; 2020 Mar; 59(5):689-694. PubMed ID: 31735793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell deformability and secondary hyperparathyroidism in uremic patients on maintenance hemodialysis.
    Docci D; Turci F; Salvi P; Pretolani E
    Artif Organs; 1984 May; 8(2):141-4. PubMed ID: 6547327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients.
    Salem MM
    Am J Kidney Dis; 1997 Jun; 29(6):862-5. PubMed ID: 9186071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal discrimination of mild hyperparathyroidism with total serum calcium, ionized calcium and parathyroid hormone measurements.
    Benson L; Ljunghall S; Groth T; Falk H; Hvarfner A; Rastad J; Wide L; Akerström G
    Ups J Med Sci; 1987; 92(2):147-76. PubMed ID: 2889282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis.
    Diao Z; Wang L; Li D; Liu W
    Ren Fail; 2017 Nov; 39(1):140-145. PubMed ID: 27845598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma intact parathyroid hormone (PTH) and PTH-related peptide in familial benign hypercalcemia: greater responsiveness to endogenous PTH than in primary hyperparathyroidism.
    Firek AF; Kao PC; Heath H
    J Clin Endocrinol Metab; 1991 Mar; 72(3):541-6. PubMed ID: 1997510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum intact parathyroid hormone and pruritus in hemodialysis patients.
    Makhlough A; Emadi N; Sedighi O; Khademloo M; Bicmohamadi AR
    Iran J Kidney Dis; 2013 Jan; 7(1):42-6. PubMed ID: 23314141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
    Yamada Y; Kumafuji M; Sodeyama T; Suzawa T; Momose M; Tokoo M
    Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.
    Tabata T; Shoji S; Morita A; Emoto M; Inoue T; Miki T; Nishizawa Y; Morii H
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S105-12. PubMed ID: 1820436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Control of calcium and phosphate in hemodialysis patients].
    Eriguchi R; Takei S; Satou Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
    Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.